Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul;31(7):50.
doi: 10.1007/s12032-014-0050-4.

GRM4 Gene Polymorphism Is Associated With Susceptibility and Prognosis of Osteosarcoma in a Chinese Han Population

Free PMC article

GRM4 Gene Polymorphism Is Associated With Susceptibility and Prognosis of Osteosarcoma in a Chinese Han Population

Chaoyin Jiang et al. Med Oncol. .
Free PMC article


Osteosarcoma (OS), the most common primary bone malignancy, occurs primarily in adolescents and young adults. In earlier genome-wide association studies, rs7591996, rs10208273, rs17206779 and rs1906953 were identified as candidate loci for OS in Caucasians but the association of these single-nucleotide polymorphisms (SNPs) with OS in a Chinese Han population remains unknown. We measured the frequency of these four variants in a Chinese Han population to better understand the genetic etiology of OS. Polymerase chain reaction sequencing was used to detect the genotypes of four candidate SNPs in peripheral blood samples collected from 168 OS patients and 216 healthy controls. Logistic regression models were used to estimate the odds ratios and 95 % confidence intervals. We found rs1906953 in the glutamate receptor metabotropic 4 (GRM4) gene was associated significantly with OS in our Chinese Han population; as with the other SNPs, however, no statistically significant difference was detected. Further analysis showed the association between rs1906953 and OS was independent of gender and age. The rs1906953 locus was not associated with Enneking stages or tumor location; however, it was associated significantly with OS metastasis and prognosis. The GRM4 gene polymorphism was associated with the susceptibility and metastasis of OS in a Chinese Han population.


Fig. 1
Fig. 1
Analysis for effects of the rs1906953 genotype on survival of the OS group

Similar articles

See all similar articles

Cited by 16 articles

See all "Cited by" articles


    1. Lietman SA, Joyce MJ. Bone sarcomas: overview of management, with a focus on surgical treatment considerations. Cleve Clin J Med. 2010;77(Suppl 1):S8–S12. doi: 10.3949/ccjm.77.s1.02. - DOI - PubMed
    1. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115(7):1531–1543. doi: 10.1002/cncr.24121. - DOI - PMC - PubMed
    1. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res. 2009;152:3–13. doi: 10.1007/978-1-4419-0284-9_1. - DOI - PubMed
    1. Benayahu D, Shur I, Marom R, Meller I, Issakov J. Cellular and molecular properties associated with osteosarcoma cells. J Cell Biochem. 2001;84(1):108–114. doi: 10.1002/jcb.1270. - DOI - PubMed
    1. Gordon N, Kleinerman ES. Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine. J Aerosol Med Pulm Drug Deliv. 2010;23(4):189–196. doi: 10.1089/jamp.2009.0812. - DOI - PMC - PubMed

Publication types

MeSH terms